RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
docetaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug
(combination chemotherapy) together with bevacizumab may kill more tumor cells.
PURPOSE: This clinical trial is studying the side effects of giving bevacizumab together with
docetaxel and cyclophosphamide and to see how well it works in treating patients with
early-stage high-risk breast cancer.
This is a single arm, non randomised pilot study investigating the safety of the combination
of Docetaxel + Cyclophosphamide+ Bevacizumab in the adjuvant treatment of patients with early
stage, HER 2 negative, high risk breast cancer.